（於中華人民共和國註冊成立的股份有限公司） 股份代號: 2120 年度報告 2024 秦 浩先生 李昌浩先生 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 財務摘要 | 4 | | 董事長致辭 | 5 | | 管理層討論與分析 | 7 | | 董事會報告 | 47 | | 監事會報告 | 64 | | 企業管治報告 | 65 | | 董事、監事及高級管理層 | 83 | | 審計報告 | 97 | | 合併資產負債表 | 103 | | 母公司資產負債表 | 106 | | 合併利潤表 | 109 | | 母公司利潤表 | 112 | | 合併現金流量表 | 114 | | 母公司現金流量表 | 117 | | 合併所有者權益變動表 | 119 | | 母公司所有者權益變動表 | 123 | | 財務報表附註 | 125 | | 釋義 | 287 | 2 2024年度報告 溫州康寧醫院股份有限公司 公司資料 董事會 執行董事 管偉立先生（ 董事長 ） 王蓮月女士 王 健先生 非執行董事 獨立非執行董事 鐘文堂女士 金 玲女士 陳世強先生 審核委員會 鐘文堂女士 （主席） 李 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截至2024年12月31日止年度業績公告 2024年，中國醫療行業在多重挑戰中呈現結構性調整態勢。過去一年，全球 經濟增速放緩，外部環境仍舊複雜多變，同時疊加國家醫保局繼續推進醫保 支付方式改革，對醫療行業提出了更高的期待和要求。從中短期看，在同業 競爭加劇、公立醫院規模擴張及醫保支付政策收緊等多重因素影響下，民營 醫院的行業生態正經歷系統性重構。報告期內，本集團以「提質增效、穩中 求進」為戰略目標，聚焦集團化資源整合、深度發掘優勢學科潛力，通過運 營效率的優化以及信息技術的賦能，強化精神醫療領域的市場地位，加速佈 局老年醫療服務業務版圖，構建多元業務增長曲綫，從而在經濟週期波動中 保持穩健的發展。 報告期內，本集團整體呈現「收入穩中有憂、利潤略有承壓」。報告期內，本 集團錄得總收入為人民幣1,654.3百萬元，較2023年增長3.6%，其中，自有 醫院運營收入達到人民幣1,517.8百萬元，較2023 ...

Revenue and Profit Performance - Total revenue for the first half of 2024 reached RMB 829.0 million, a 6.6% increase compared to the same period last year[19] - Revenue from self-operated hospitals amounted to RMB 765.6 million, a 5.1% year-on-year growth[19] - Net profit attributable to shareholders of the company was RMB 50.7 million, up 15.9% from the previous year[19] - The company's total revenue for the first half of 2024 reached RMB 829.0 million, a 6.6% increase compared to the same period in 2023[25] - Net profit attributable to shareholders increased by 15.9% year-over-year to RMB 50.7 million in the first half of 2024[25] - The company's self-operated hospitals achieved a gross profit margin of 27.5% in the first half of 2024, up from 24.9% in the same period in 2023[25] - The company's self-operated hospitals generated billable revenue of RMB 784.9 million, a 5.5% increase compared to the same period in 2023[27] - The company's self-operated hospitals achieved a gross profit of RMB 229.7 million, a 16.8% increase compared to the same period in 2023[28] - Total revenue for the first half of 2024 reached RMB 828.96 million, a 6.56% increase compared to RMB 777.93 million in the same period last year[116] - Net profit for the first half of 2024 was RMB 44.99 million, a decrease of 7.66% from RMB 48.73 million in the same period last year[118] - Operating profit for the first half of 2024 was RMB 63.83 million, a 12.97% increase compared to RMB 56.50 million in the same period last year[118] - Net profit for the period was RMB 29,384,349.62, compared to a net loss of RMB -8,676,844.29 in the previous period[120] - Comprehensive income attributable to the parent company was RMB 50,723,744.20, compared to RMB 43,750,057.46 in the previous period[119] Hospital Operations and Performance - The number of self-operated hospitals remained at 32, with the number of operational beds increasing to 11,648 from 11,268 at the end of 2023[19] - Some hospitals, such as Huainan Kangning Hospital and Changchun Kanglin Psychological Hospital, showed significant performance growth due to refined management measures[22] - Hospitals like Beijing Yining Hospital and Shenzhen Yining Hospital faced challenges due to high property costs, leading to cumulative losses[22] - Revenue from self-operated hospitals accounted for RMB 765.6 million, representing 31.1% of the company's total self-operated hospital revenue, with the elderly medical sector showing initial scale[24] - The company operates 6 elderly hospitals and has 1 health care project under construction, with a total of approximately 2,730 beds[24] - The elderly medical sector generated revenue of RMB 238.1 million in the first half of 2024, with some hospitals showing significant growth compared to the same period in 2023[24] - Hospital bill income increased by 6.2% to RMB 677.2 million, driven by a 15.2% growth in hospital bed days due to new acquisitions and expansions[32] - Outpatient bill income slightly increased by 1.2% to RMB 107.7 million, with outpatient visits decreasing by 3.0% but average outpatient spending per visit rising by 4.2%[32] - Treatment and general medical service income grew by 5.2%, accounting for 78.7% of the hospital's operating income, while drug sales income increased by 6.5%, making up 21.3%[32] - Outpatient visits totaled 243,108 in the first half of 2024, with outpatient revenue reaching RMB 107.7 million[29] Financial Position and Cash Flow - Operating cash flow for the first half of 2024 was RMB 116.5 million, compared to RMB 113.6 million in the same period last year[17] - Total assets as of June 30, 2024, were RMB 3,008.4 million, slightly down from RMB 3,047.7 million at the end of 2023[18] - Total liabilities decreased to RMB 1,581.9 million from RMB 1,639.5 million at the end of 2023[18] - Equity attributable to shareholders of the company increased to RMB 1,290.9 million from RMB 1,265.1 million at the end of 2023[18] - The company's own hospital revenue costs increased by 1.4% to RMB 555.2 million, with employee benefits and expenses rising by 9.3% and drug and consumable costs decreasing by 6.1%[33] - Gross profit for the company's own hospital business increased by 16.1% to RMB 210.4 million, with the gross margin rising to 27.5%, up 2.6 percentage points from the previous year[37] - Other medical-related business income reached RMB 63.0 million, with non-hospital drug and medical device sales contributing RMB 41.7 million[34] - Property rental income decreased significantly to RMB 0.3 million due to new lease conditions and the return of subleased properties[35] - Management expenses increased by 4.3% to RMB 106.3 million, primarily due to a 15.1% rise in employee benefits and expenses[41] - The company's comprehensive gross margin improved to 27.3%, up from 25.9% in the previous year[37] - Sales expenses increased to RMB 9.2 million, accounting for 1.2% of the company's own hospital operating income[39] - R&D expenses increased by 17.6% to RMB 17.6 million, accounting for 2.3% of the company's self-operated hospital revenue[43] - Net financial expenses rose to RMB 24.5 million, with interest expenses on borrowings increasing by RMB 4.0 million compared to the same period in 2023[45] - Investment income reached RMB 1.7 million, primarily due to a RMB 1.4 million gain from the disposal of equity in Hangzhou Yining Hospital[46] - Credit impairment losses increased to RMB 5.6 million, up from RMB 3.0 million in the same period last year[47] - Non-operating income decreased by RMB 5.4 million to RMB 0.5 million, mainly due to a RMB 5.5 million reduction in donations received[49] - Income tax expenses grew by 43.9% to RMB 16.5 million, with the effective tax rate rising to 26.9% from 19.1%[50] - Accounts receivable increased by 6.6% to RMB 448.1 million, with a turnover period of 95 days[54] - Construction in progress rose to RMB 234.0 million, primarily due to new projects at Lucheng Yining Hospital and Linhai Cining Hospital[56] - Net cash generated from operating activities amounted to RMB 116.5 million, including a net profit of RMB 45.0 million and adjustments for depreciation and amortization of RMB 79.4 million[62] - Net cash used in investing activities amounted to RMB 112.7 million, primarily due to the purchase of property, plant, and equipment totaling RMB 111.0 million, including infrastructure investments in hospitals such as Lucheng Yining Hospital and Quzhou Yining Hospital[63] - Net cash outflow from financing activities was RMB 41.7 million during the reporting period[66] - Bank loan balance as of June 30, 2024, was RMB 923.3 million, an increase from RMB 864.7 million as of December 31, 2023, driven by repayments of RMB 304.8 million and new borrowings of RMB 363.4 million[66] - The company's asset-liability ratio slightly decreased to 52.6% as of June 30, 2024, compared to 53.8% as of December 31, 2023[72] - The company had 4,742 employees as of June 30, 2024, with total employee compensation (including salaries and benefits) of approximately RMB 313.8 million, up from RMB 291.5 million in the same period last year[73] - The average employee salary (including social insurance and housing fund contributions) was RMB 132.4 thousand per year[73] - The company's lease liabilities, excluding amounts due within one year, stood at RMB 158.9 million as of June 30, 2024[69] - The company did not engage in any significant investments, acquisitions, or disposals during the six months ended June 30, 2024[66] - Total assets as of June 30, 2024, amounted to RMB 3,008,351,772.44, a slight decrease from RMB 3,047,686,606.84 at the end of the previous year[109] - Current assets totaled RMB 957,021,290.30, with cash and cash equivalents at RMB 373,302,433.47, down from RMB 418,861,721.39 at the end of the previous year[108] - Non-current assets amounted to RMB 2,051,330,482.14, including fixed assets of RMB 782,127,103.00 and intangible assets of RMB 307,875,476.38[109] - Long-term equity investments increased to RMB 141,550,815.01 from RMB 139,071,987.05 at the end of the previous year[109] - Accounts receivable increased to RMB 448,102,421.02 from RMB 420,441,069.56 at the end of the previous year[108] - Inventory decreased to RMB 51,889,640.76 from RMB 60,600,180.25 at the end of the previous year[108] - Construction in progress increased significantly to RMB 234,034,296.61 from RMB 186,980,240.67 at the end of the previous year[109] - Total liabilities decreased to RMB 1,581,889,916.28 from RMB 1,639,480,660.02 compared to the end of the previous year[111] - Total owner's equity increased to RMB 1,426,461,856.16 from RMB 1,408,205,946.82[111] - Short-term borrowings decreased to RMB 111,000,000.00 from RMB 127,001,700.00[110] - Accounts payable increased to RMB 112,544,938.03 from RMB 110,060,007.67[110] - Long-term borrowings increased to RMB 768,224,669.65 from RMB 557,719,214.69[110] - Total current assets increased to RMB 856,201,535.51 from RMB 847,091,576.19[112] - Long-term equity investments increased to RMB 793,380,629.16 from RMB 785,983,439.17[113] - Fixed assets decreased to RMB 283,949,624.57 from RMB 288,701,322.35[113] - Intangible assets decreased to RMB 23,105,075.42 from RMB 23,680,002.23[113] - Total assets increased to RMB 2,068,476,006.37 from RMB 2,050,057,345.62[113] - Total liabilities as of June 30, 2024, amounted to RMB 804.83 million, a slight increase from RMB 794.29 million at the end of the previous year[114] - Short-term borrowings decreased by 11.20% to RMB 111.00 million as of June 30, 2024, compared to RMB 125.00 million at the end of the previous year[114] - Long-term borrowings increased by 39.85% to RMB 506.30 million as of June 30, 2024, compared to RMB 362.04 million at the end of the previous year[114] - Total equity as of June 30, 2024, was RMB 1.26 billion, a slight increase from RMB 1.26 billion at the end of the previous year[115] - R&D expenses for the first half of 2024 were RMB 17.59 million, a 17.58% increase compared to RMB 14.96 million in the same period last year[116] - Financial expenses for the first half of 2024 were RMB 24.47 million, a 21.36% increase compared to RMB 20.16 million in the same period last year[116] - The company's total assets as of June 30, 2024, were RMB 2.07 billion, a slight increase from RMB 2.05 billion at the end of the previous year[115] - Operating revenue for the period was RMB 193,286,941.03, an increase from RMB 176,204,799.00 in the previous period[120] - Basic earnings per share (EPS) for the period was RMB 0.68, up from RMB 0.59 in the previous period[119] - Cash flow from operating activities was RMB 116,535,983.61, slightly higher than RMB 113,591,338.70 in the previous period[122] - Sales of goods and services generated RMB 774,736,897.94 in cash, down from RMB 780,086,767.35 in the previous period[122] - R&D expenses increased to RMB 12,778,787.81 from RMB 9,690,626.11 in the previous period[120] - Investment income for the period was RMB 14,189,338.60, compared to a loss of RMB -775,547.72 in the previous period[120] - Interest expenses for the period were RMB 13,692,407.18, up from RMB 11,787,407.21 in the previous period[120] - Investment activities generated a net cash outflow of RMB 112.71 million, compared to RMB 119.12 million in the previous period[123] - Financing activities resulted in a net cash outflow of RMB 41.66 million, a significant decrease from the net inflow of RMB 9.79 million in the previous period[123] - The company's cash and cash equivalents decreased by RMB 37.93 million, compared to an increase of RMB 4.27 million in the previous period[124] - Operating activities generated a net cash inflow of RMB 20.38 million, down from RMB 53.71 million in the previous period[124] - The company received RMB 362.77 million in borrowings, an increase from RMB 251.05 million in the previous period[123] - The company repaid RMB 304.77 million in debt, significantly higher than the RMB 109.63 million repaid in the previous period[123] - The company invested RMB 111.00 million in fixed assets, intangible assets, and other long-term assets, slightly higher than the RMB 107.84 million invested in the previous period[123] - The company's cash and cash equivalents balance at the end of the period was RMB 366.79 million, compared to RMB 262.87 million in the previous period[124] - The parent company's cash and cash equivalents decreased by RMB 19.60 million, compared to an increase of RMB 45.81 million in the previous period[125] - The parent company received RMB 293.00 million in borrowings, an increase from RMB 199.05 million in the previous period[125] - Total owner's equity as of June 30, 2024, was RMB 1,408,205,946.82, with minority interests amounting to RMB 143,141,250.58[126] - The company's capital reserve remained unchanged at RMB 38,399,577.13 for the period[126][129] - Net profit attributable to the parent company's owners decreased by RMB 11,942,120.95 compared to the previous period[126] - Owner's equity decreased by RMB 8,566,709.51 due to capital reduction and owner's investment[126][143] - The company's share capital remained stable at RMB 74,600,300.00[126][153] - Comprehensive income for the period showed a decrease of RMB 2,382,931.61 compared to the previous period[129] - The company's undistributed profit decreased by RMB 22,380,090.00 due to profit distribution[139] - Total owner's equity at the beginning of the year was RMB 1,265,064,696.24[126] - The company's special reserve decreased by RMB 3,375,411.44 during the period[126] - Owner's equity at the end of the period was RMB 1,263,645,164.63[140] - Total owner's equity as of June 30, 2024, is RMB 1,226,134,196.95[161] - Undistributed profits amount to RMB 241,903,691.18[161] - Surplus reserve stands at RMB 38,399,577.13[161] - The company's registered capital is RMB 74,600,300.00[162] - Cumulative issued share capital as of June 30, 2024, is 74.60 million shares[163] - The company's main business activities include operating psychiatric hospitals and providing hospital management services[163] - The company's actual controllers are Guan Weili and his spouse Wang Lianyue[163] - The company's income tax rate is 15%[166] - The company's subsidiary, Zhejiang Jieling Health Technology Co., Ltd., has a 15% income tax rate[167] - The company has applied for high-tech enterprise qualification and expects to receive the certificate by December 2024, which would reduce its income tax rate to 15%[167] - Total monetary funds decreased to RMB 373.3 million from RMB 418.9 million at the end of the previous year, with bank deposits accounting for the majority at RMB 367.2 million[169] - Trading financial assets increased slightly to RMB 7.6 million, all of which are equity instrument investments[170] - Accounts receivable increased to RMB 500.9 million, with 88.6% (RMB 443.6 million) within 1 year and bad debt provision increased to RMB 52.8 million[173] - Significant bad debt provision for patient medical fee arrears was RMB 24.3 million, representing 84.56% of the total amount[175] -

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. 截至2024年6月30日止六個月的半年度業績公告 1 引言 1.1 董事會欣然宣佈本集團於本報告期之未經審核半年度業績，以及連同截至 2023年6月30日止六個月的數字比較。 1.2 本集團於本報告期的財務報告（「財務報告」）乃按中國企業會計準則編製。 1 2 財務摘要 2.1 主要財務數據及指標 | --- | --- | --- | |--------------------------|---------------------------------------|-----------------------------------| | | 截至 6 月 30 \n2024 年 \n人民幣千元 | 日止六個月 \n2023 年 \n人民幣千元 | | | （未經審核） | （未經審核） | | | ...

Financial Performance - Total revenue for 2023 reached RMB 1,596.3 million, a 7.5% increase compared to 2022[4] - Revenue from self-operated hospitals in 2023 was RMB 1,485.2 million, an 8.7% increase from 2022[4] - Net profit attributable to shareholders in 2023 was RMB 85.9 million, turning a profit compared to 2022[4] - The company's ROE (Return on Equity) for 2023 was 7.0%[4] - Revenue for 2023 reached RMB 1,596,266 thousand, a 7.5% increase from RMB 1,484,903 thousand in 2022[27] - Net profit attributable to the company's shareholders in 2023 was RMB 85,948 thousand, a significant improvement from a loss of RMB 24,221 thousand in 2022[27] - Total assets increased to RMB 3,047,687 thousand in 2023, up 15.5% from RMB 2,637,787 thousand in 2022[27] - Total liabilities rose to RMB 1,639,481 thousand in 2023, a 24.9% increase from RMB 1,311,885 thousand in 2022[27] - The company's equity attributable to shareholders grew to RMB 1,265,065 thousand in 2023, up 5.3% from RMB 1,201,585 thousand in 2022[27] - Total revenue for 2023 reached RMB 1,596.3 million, a 7.5% increase compared to 2022[63] - Revenue from self-operated hospitals grew to RMB 1,485.2 million, an 8.7% increase year-over-year[63] - Net profit attributable to shareholders was RMB 85.9 million, turning around from a loss in 2022, with a return on equity of 7.0%[63] - The company achieved revenue of RMB 1,596.3 million in 2023, a 7.5% increase compared to 2022, with self-operated hospital revenue reaching RMB 1,485.2 million, an 8.7% increase[71] - Gross profit margin for self-operated hospitals improved to 25.4% in 2023, up from 23.9% in 2022, with overall gross profit increasing by 16.5% to RMB 411.1 million[71] - Net profit attributable to shareholders was RMB 85.9 million in 2023, turning around from a loss in 2022[71] - Operating cash flow increased by 16.6% to RMB 265.0 million in 2023 compared to RMB 227.2 million in 2022[71] - Self-operated hospital billable revenue reached RMB 1,537.4 million in 2023, a 7.9% increase, driven by growth in outpatient and inpatient visits[73] - Variable consideration decreased to RMB 52.2 million in 2023, accounting for 3.4% of billable revenue, down from 4.1% in 2022[73] - Public medical insurance settlements accounted for 68.7% of the company's cash received from sales and services in 2023, maintaining a similar proportion to previous years (68.6% in 2021 and 69.3% in 2022)[69] - The company's self-operated hospital billable revenue increased to RMB 1,537,406 thousand in 2023 from RMB 1,425,005 thousand in 2022[94] - The company's outpatient billable revenue reached RMB 218.3 million in 2023, a 5.6% increase compared to 2022, despite a 5.0% decrease in outpatient visits[101] - The average outpatient expenditure per visit increased by 11.2% to RMB 436 in 2023[99] - The company's gross profit from self-operated hospitals increased to RMB 429,486 thousand in 2023 from RMB 384,890 thousand in 2022[96] - The company's treatment and general medical service revenue reached RMB 1,214,672 thousand in 2023, up from RMB 1,119,887 thousand in 2022[99] - The company's drug sales revenue increased to RMB 322,734 thousand in 2023 from RMB 305,118 thousand in 2022[99] - The company's own hospital revenue costs increased to RMB 1,107.9 million, a 6.5% growth compared to 2022, driven by a 7.7% increase in drug and consumable expenses, an 11.6% rise in employee benefits and expenses due to increased hospital beds, and a 9.1% decrease in asset depreciation and amortization[105] - The gross margin for the company's own hospital business increased to 25.4% in 2023 from 23.9% in 2022, while the overall gross margin rose to 25.8% from 23.8%[106] - The company's own hospital billable income increased by RMB 112.4 million compared to 2022, with a gross profit growth of 11.6% due to increased inpatient bed days and cost control[119] - The number of inpatient beds at the end of the period was 11,268, up from 9,688 in 2022, with an effective inpatient service bed day capacity of 4,112,820, compared to 3,536,120 in 2022[120] - Inpatient billable income reached RMB 1,319.1 million, an 8.3% increase from 2022, driven by a 10.7% growth in inpatient bed days[121] - The company's total gross profit reached RMB 411.1 million, a 16.5% increase from 2022, with the gross profit of the own hospital business reaching RMB 377.2 million, a 15.5% growth[125] - The company's comprehensive gross margin increased to 25.8% in 2023 from 23.8% in 2022, with the gross margin of the own hospital business growing by 1.5 percentage points[126] - Management expenses were RMB 213.0 million, a 3.5% increase from 2022, with employee benefits and expenses rising by 5.5%[129] - R&D expenses were RMB 32.5 million, a 1.7% decrease from 2022, accounting for 2.2% of the company's own hospital operating income[131] - The company's net financial expenses were RMB 41.5 million, a decrease of RMB 2.9 million from 2022, with a 9.1% reduction in loan interest expenses due to lower bank loan interest rates[111] - Credit impairment losses decreased to RMB 9.4 million in 2023 from RMB 25.2 million in 2022[133] - Investment losses amounted to RMB 6.1 million, including a one-time impairment of RMB 6.8 million due to the acquisition of Chengdu Yining Hospital[154] - Accounts receivable increased by 9.8% to RMB 420.4 million as of December 31, 2023, driven by increased revenue from the company's self-operated hospitals[137] - Construction in progress increased to RMB 187.0 million, primarily due to new construction projects at Lucheng Yining Hospital and Linhai Cining Hospital[139] - Net cash generated from operating activities was RMB 265.0 million, including net profit of RMB 85.9 million and adjustments for depreciation and amortization of RMB 159.4 million[142] - Net cash used in investing activities was RMB 215.0 million, mainly due to the purchase of property, plant, and equipment totaling RMB 179.7 million[143] - Income tax expense decreased by 53.9% to RMB 12.3 million, with the effective tax rate dropping to 12.4% from 170.3% in 2022[135] - Sales expenses increased to RMB 17.1 million, accounting for 1.2% of the company's self-operated hospital revenue[149] - Other receivables and prepayments increased to RMB 79.5 million as of December 31, 2023, up from RMB 69.4 million in 2022[138] - Inventory balance increased to RMB 60.6 million, primarily consisting of pharmaceutical stock and consumables[159] - Right-of-use assets decreased to RMB 189.1 million as of December 31, 2023 (RMB 190.4 million as of December 31, 2022), mainly due to depreciation[162] - Bank loan balance increased to RMB 864.7 million as of December 31, 2023 (RMB 616.5 million as of December 31, 2022), with repayments of RMB 357.7 million and new borrowings of RMB 605.9 million during the reporting period[167] - Lease liabilities totaled RMB 163.2 million as of December 31, 2023, excluding RMB 28.6 million due within one year[169] - The company had 4,765 full-time employees as of December 31, 2023 (4,196 as of December 31, 2022), with total employee compensation of RMB 607.4 million (RMB 529.4 million in 2022) and average annual compensation of RMB 127.5 thousand[170] - The net cash generated from financing activities for the reporting period was RMB 96.1 million[187] - The total mortgage loan balance as of December 31, 2023, was RMB 260.0 million for Wenzhou Kangning Hospital, RMB 75.1 million for Wenzhou Lucheng Yining Hospital, RMB 25.0 million for Jinyuan Shuning Hospital, and RMB 37.7 million for Quzhou Yining Hospital[188] - The asset-liability ratio increased slightly to 53.8% as of December 31, 2023, compared to 49.7% as of December 31, 2022, primarily due to an increase in bank borrowings[190] Hospital Operations and Expansion - The number of self-operated hospitals increased from 29 at the end of 2022 to 32 at the end of 2023[4] - Operational beds increased from 9,688 at the end of 2022 to 11,268 at the end of 2023[4] - The company acquired controlling stakes in Loudi Kangning Hospital, Dongkou Lening Hospital, and Chengdu Yining Hospital in 2023[4] - The number of self-operated hospitals increased to 32, including one independent internet hospital (Yining Psychological Internet Hospital)[63] - Operational beds expanded to 11,268, up from 9,688 at the end of 2022[63] - The company acquired 51% equity in Loudi Kangning Hospital and Dongkou Lenning Hospital, and completed the acquisition of Chengdu Yining Hospital to expand its mental health specialty network[66] - The company's regional management model showed increasing agglomeration effects, with self-operated hospitals in Taizhou and Haixi regions achieving stable year-on-year growth[64] - The company operates 6 elderly hospitals with approximately 2,540 beds as of December 31, 2023[88] - The company is actively promoting hospital rating evaluations to improve service quality and competitiveness, with its flagship hospital successfully passing the third-level A-grade psychiatric hospital review[89] - The company's own hospital billable income increased by RMB 112.4 million compared to 2022, with a gross profit growth of 11.6% due to increased inpatient bed days and cost control[119] - The number of inpatient beds at the end of the period was 11,268, up from 9,688 in 2022, with an effective inpatient service bed day capacity of 4,112,820, compared to 3,536,120 in 2022[120] - Inpatient billable income reached RMB 1,319.1 million, an 8.3% increase from 2022, driven by a 10.7% growth in inpatient bed days[121] Strategic Focus and National Policies - The company is upgrading its internet hospital platform and strengthening its pharmaceutical supply chain[4] - The company is focusing on the development of mental health and elderly medical services, aligning with national health strategies[3][8] - The Chinese government has set a goal to build a social environment conducive to the mental health of children and adolescents by 2022, with a focus on prevention and intervention measures for mental health issues and disorders[12] - By 2025, China plans to construct 100 mental health welfare facilities in regions with insufficient mental health service capabilities, targeting vulnerable populations such as children and individuals with mental disorders[13] - The "14th Five-Year Plan" for public services emphasizes expanding the scale of psychiatrists and registered nurses, improving mental health diagnosis and treatment capabilities, and encouraging social forces to participate in the supply of medical services[14] - By 2050, China's elderly population aged 60 and above is projected to exceed 500 million, accounting for 38.81% of the total population, signaling a significant market opportunity in elderly healthcare[15] - The Chinese government has issued policies encouraging private capital to participate in the elderly care industry, promoting the integration of medical and elderly care services[15] - The State Council has advocated for the development of smart elderly care services, leveraging internet resources and social forces to provide home-based care services such as health management and rehabilitation[16] - The Zhejiang Provincial Health Commission supports the development of specialized hospitals, particularly in areas like rehabilitation, nursing, and elderly care, encouraging chain and brand development[14] - The Chinese government has introduced policies to support the establishment of medical and elderly care integration institutions, addressing the growing demand for elderly health services[16] - The company emphasized the importance of expanding elderly care, rehabilitation, and maternal care services in line with national policies[42][55][57][59][60][61] - The company is focusing on the growing demand for mental health and elderly medical services, leveraging the window of opportunity created by the "Healthy China" strategy[70] - The company's elderly medical business achieved revenue of approximately RMB 427.1 million in 2023, accounting for 28.8% of the group's self-operated hospital revenue[88] Equity Incentive and Shareholder Information - The company plans to distribute at least 30% of annual net profit as cash dividends from 2023 to 2027, with the goal of increasing this ratio to 50%[7] - No shares were awarded, canceled, or expired under the H-share incentive trust plan during the reporting period[30] - The total number of incentive shares granted under the H-share incentive trust plan and other share plans must not exceed 1% of the company's issued share capital[31] - No shareholders waived or agreed to waive any dividends as of December 31, 2023[34] - The company's main business location is in Wenzhou, Zhejiang Province, China[23] - The company's H-share trading price was approximately HKD 40.00 per share (approximately RMB 32.50 per share) as of May 29, 2018[29] - The company granted a total of 2,454,632 incentive shares to employees, with 133,715 shares granted to senior management and 1,684,814 shares to core technical personnel[43] - No securities were issued during the reporting period[49] - No management contracts were signed for the entire business or main business during the reporting period[51] - The company did not have any approved indemnity provisions as of December 31, 2023[47] - The equity incentive plan granted a total of 2,460,000 shares, representing 3.30% of the company's total share capital and 4.45% of non-tradable domestic shares[179] - The equity incentive plan had 193 grantees, with 1,818,529 shares granted in the first phase, 180,516 shares in the second phase, and 540,229 shares in the third phase[173] - The equity incentive plan has a 48-month lock-up period from the grant date, with a grant price of RMB 10.47 per share[173] - The company had no significant investments, acquisitions, or disposals during the reporting period[166] - The equity incentive plan allows grantees to indirectly hold company shares through a limited partnership employee持股平台[177] - The equity incentive plan grants grantees rights such as dividends and voting rights, which are not restricted by the lock-up period[177] - The company implemented an H-share incentive trust plan to retain core technical and management personnel, approved at the 2023 first extraordinary general meeting on September 27, 2023[186] - The company revised the 2018 equity incentive plan in 2021, removing performance assessment requirements and the obligation to repurchase unvested incentive shares[191] - The equity incentive plan aims to align the interests of shareholders, the company, and the core team, ensuring long-term development and strategic goals[193] - The scope of incentive targets includes directors, supervisors, senior management, core technical (business) personnel, and other personnel deemed necessary by the board of directors[194] - The specific list of incentive targets and their subscription amounts will be determined by the board of directors[195] - The equity incentive plan involves the form of equity, the source and type of shares, and the quantity and proportion of shares relative to the company's total share capital[196] - The equity incentive plan has a validity period of 10 years from April 26, 2018, with approximately 4 years remaining as of the report date[198] - The lock-up period for incentive shares is 48 months from the date of grant[199] - The first batch of incentive shares was fully unlocked on June 28, 2022, 48 months after the initial grant date (June 29, 2018)[200] Risks and Challenges - The company faces risks of professional medical talent shortages, which could impact its ability to provide ideal medical services[90]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 1 3.1 業績回顧 報告期內，為了能夠全面統籌推動醫療質量、醫療服務及科研教學的協同發 展，為患者提供更加優質醫療服務，更好滿足精神病人多層次、多樣化的健 康需求，本集團積極開展自有醫院等級評審工作，其中：旗艦醫院溫州康寧 醫院順利通過浙江省第四週期三級甲等精神專科醫院複評工作，本集團旗下 的臨海康寧醫院、蒼南康寧醫院、平陽康寧醫院、平陽長庚怡寧醫院、永嘉 康寧醫院、樂清康寧醫院和青田康寧醫院已順利通過浙江省第四週期二級醫 院評審，未來，本集團將繼續逐一開展自有醫院的等級創建工作，不斷提高 綜合競爭力，進一步鞏固市場競爭地位。 5 下表載列於所示期間總收入明細： | --- | --- | --- | |---------------------------------|--------------------------------------------|--------------------- ...

（二十）交易性金融負債 （二十一）應付票據 （二十二）應付賬款 （二十三）預收款項 溫州康寧醫院股份有限公司 2023 中期報告 83 截至2023年6月30日止6個月期間 （除特別註明外，金額單位為人民幣元） （二十四）應付職工薪酬 | --- | --- | --- | --- | --- | --- | |--------------|---------------------------------------|--------------------------------|-----------------------------|-----------------------------|--------------------------| | 項目 \n(1) | 短期薪酬列示 \n工資、獎金、津貼和補貼 | 上年年末餘額 \n66,161,148.57 | 本期增加 \n246,166,417.83 | 本期減少 \n254,298,788.29 | 期末餘額 \n58,206,945.42 | | (2) | 職工福利費 | 307,382.14 | 8,945,632.04 | 9,1 ...

Financial Performance - The group's inpatient revenue for the period was RMB 637.8 million, an increase of 8.4% compared to the same period in 2022, driven by a 6.8% increase in inpatient bed days[12]. - Total revenue for the six months ended June 30, 2023, was RMB 777.9 million, an increase of 5.4% compared to RMB 738.3 million for the same period in 2022[40]. - Revenue from self-operated hospitals reached RMB 728.7 million, up RMB 54.6 million or 8.0% year-on-year, primarily driven by growth in several hospitals[46]. - The group’s total revenue for the first half of 2023 was RMB 777.9 million, an increase of 5.4% compared to RMB 738.3 million in the same period last year[69]. - The operating income from self-owned hospitals was RMB 728.7 million, reflecting a growth of 6.7% year-on-year[71]. - The net profit attributable to shareholders was RMB 43.8 million, representing a 12.8% increase from RMB 38.8 million in the previous year[75]. - The gross profit margin for self-owned hospitals decreased to 24.9% from 26.5% in the same period last year[75]. - The group recorded a decrease in accounts receivable turnover days to 91 days, compared to 90 days in the previous year[61]. - The total comprehensive income attributable to shareholders of the parent company for the first half of 2023 was RMB 43,750,058, compared to RMB 48,729,233 in 2022, indicating a decline of 10.1%[136]. Operational Metrics - As of June 30, 2023, the group owned 30 hospitals, an increase from 29 as of December 31, 2022, with total operational bed capacity rising to 10,578 beds from 9,688 beds[3]. - The average daily expenditure per inpatient bed increased by 1.5%, while the inpatient revenue accounted for 85.7% of total operating revenue from owned hospitals[12]. - Outpatient revenue reached RMB 106.4 million, reflecting a 5.4% increase year-over-year, attributed to an 11.4% rise in outpatient visits[23]. - The total number of outpatient visits was 250,648, up from 225,032 in the previous year[11]. - The proportion of treatment and general medical service revenue increased to 78.9% of self-operated hospital revenue, up from 78.6% in the same period last year[47]. - The group's self-owned hospital billing revenue for the period was RMB 744.2 million, an increase of 7.9% compared to the same period in 2022, driven by an increase in outpatient and inpatient visits[78]. - Revenue from treatment and general medical services was RMB 587.2 million, up from RMB 542.0 million in the same period last year, representing an increase of 8.3%[79]. Expenses and Costs - Operating expenses increased to RMB 547.5 million, a rise of 9.0% compared to the same period in 2022, mainly due to increased employee benefits and expenses related to the growth in drug sales[49]. - Total operating costs for the six months ended June 30, 2023, were RMB 724,044,724, an increase of 6.5% from RMB 680,267,108 in 2022[124]. - Employee compensation for the period was approximately RMB 291.5 million, compared to RMB 245.3 million for the same period last year, indicating a year-over-year increase of 18.8%[90]. - Financial expenses decreased to RMB 20,159,634 in the first half of 2023 from RMB 21,648,129 in 2022, a reduction of 6.9%[124]. Cash Flow and Financial Position - Net cash generated from operating activities was RMB 113.6 million, significantly higher than RMB 56.0 million for the same period in 2022[38]. - The company reported a net increase in cash and cash equivalents of RMB 4.3 million, compared to an increase of RMB 86.4 million in the same period last year[38]. - The company's cash flow from operating activities showed a significant increase, reflecting improved operational efficiency and cash management strategies[136]. - Cash inflow from operating activities for the six months ended June 30, 2023, was $949,990,763, an increase of 33.6% compared to $710,947,438 in 2022[153]. - The ending balance of cash and cash equivalents as of June 30, 2023, was $262,868,905, a decrease from $275,180,571 in 2022[155]. - The total assets as of June 30, 2023, amounted to RMB 2,744.2 million, an increase from RMB 2,637.8 million at the end of 2022[69]. - The total liabilities increased to RMB 1,361.7 million from RMB 1,311.9 million at the end of 2022[69]. - The company's equity attributable to shareholders increased to RMB 1,242,977,776 as of June 30, 2023, from RMB 1,201,584,945 at the end of 2022, marking a growth of 3.4%[132]. Strategic Initiatives - The group has established a special fund to assist impoverished mental health patients in collaboration with charitable organizations[3]. - The group actively engaged in social responsibility initiatives, including partnerships with medical institutions to enhance mental health services in remote areas[3]. - The group plans to propose an interim dividend distribution date no later than November 30, 2023, pending shareholder approval[93]. - The company plans to implement an equity incentive plan to motivate senior management and key technical personnel[110]. - The company plans to expand its market presence through strategic acquisitions and new product launches in the upcoming quarters[145]. - Research and development efforts are focused on innovative technologies aimed at enhancing product offerings and customer experience[145]. - The company anticipates a positive outlook for the next fiscal year, with projected revenue growth driven by increased demand and market expansion strategies[145].

溫州康寧醫院股份有限公司 Wenzhou Kangning Hospital Co., Ltd. (於中華人民共和國註冊成立的股份有限公司) 股份代號: 2120 2022 年 度 報 告 32 96 83 259 公司資料 公司資料 2022 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 4 主要財務數據及指標 2022 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 5 首先，我謹代表溫州康寧醫院股份有限公司董事會，欣然提呈本集團截至2022年12月31日止年度（「2022財政年度」）之年 報。 2022 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 6 知者不惑，仁者不憂，勇者不懼。展望未來，本集團將上下齊心、凝聚合力，與時俱進、開拓創新，不斷提高站位，奮力 創造新奇蹟、展現新氣象，以新的偉大奮鬥創造新的「康寧」偉業！ 2022 年度報告 溫 州 康 寧 醫 院 股 份 有 限 公 司 7 心理健康和精神衛生事業關乎人民群眾身心健康，深刻影響經濟社會的發展，作為重大公共衛生和民生問題，也是全面實 施健康中國戰略不容忽視的關鍵領域和重要內容。 管理層討論與分析 2022年 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 截至2022年12月31日止年度業績公告 1 引言 1.1 溫州康寧醫院股份有限公司（「本公司」）之董事會（「董事會」）欣然宣佈本公司 連同其附屬公司（合稱「本集團」或「我們」）截至2022年12月31日止財政年度 「本報告期」）之合併全年業績，連同上一個財政年度（截至2021年12月31日 止財政年度）的數字比較。 1.2 本集團於本報告期的財務報表（「財務報表」）乃按中國企業會計準則編製。 1.3 報告期間，本集團存在前期會計差錯更正需追溯的若干事項，已對2021年的 財務數據進行相應重述，詳情請見本公告「重大事項－前期會計差錯更正」一 節。 ...